-
1 Comment
From a valuation standpoint, the stock is 76.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 315.5.
Based on the above factors, Vallon Pharmaceuticals Inc. Common Stock gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | US92023M1018 |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Dividend Yield | 0.0% |
|---|---|
| Beta | -1.15 |
| Market Cap | 5M |
| PE Ratio | None |
| Target Price | 12 |
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VLON using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
